Multi-page Rx ads may lack fair balance if risk info isn't facing/full page

DisputedwarningBinding lawCheckable — presence or a literal match settles it

Rule

A multi-page prescription drug advertisement in which side effect and contraindication information is presented as a distinct part MAY be found lacking in fair balance or otherwise misleading under 21 CFR 202.1(e)(7)(xi) if that information is not presented on a page facing another page of the advertisement, or on another full page.

Check

For prescription drug print ads running on more than one page where side effect and contraindication information is presented as a distinct part, confirm that this part appears on a page facing another page of the same advertisement or on another full page; if it does not, flag as a potential fair-balance deficiency under 21 CFR 202.1(e)(7)(xi).

Escalate when

Escalate when it is unclear whether the piece qualifies as a multi-page advertisement subject to 202.1 (e.g., unconventional digital pagination, spreads, or foldouts), whether the drug is a prescription (versus OTC) product, or whether the side effect/contraindication content genuinely constitutes a 'distinct part' rather than being integrated throughout the copy.

Where this comes from

21 CFR 202.1(e)(7)(xi). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…d contraindications. (x) In an advertisement promoting use of the drug in a selected class of patients (for example, geriatric patients or depressed patients), fails to present with adequate emphasis the significant side effects and contraindications or the significant dosage considerations, when dosage recommendations are included in an advertisement, especially applicable to that selected class of patients. (xi) Fails to present on a page facing another page (or on another full page) of an advertisement on more than one page, information relating to side effects and contraindications when such information is in a distinct part of the advertisement. (xii) Fails to include on each page or spread of an advertisement the information relating to side effects and contraindications or a prominent reference to its presence and location when it is presented as a distinct part of an advertisement. (xiii) Contains information from published or unpublished reports or opinions falsely or misleadingly represented or suggested to be authentic or authoritative. (f)-(i) [Re…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Mediumprint

Regulatory classprescription-drug

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quoted clause is genuinely (e)(7)(xi) and the locator matches the source text; the substance of the rule (distinct risk section in a multi-page ad must sit on a page facing another ad page or on another full page) tracks the clause word for word, so the rule is supported in substance.
- Overstatement: (e)(7)(xi) sits under the chapeau 'Advertisements that may be false, lacking in fair balance, or otherwise misleading. An advertisement may be false, lacking in fair balance, or otherwise misleading ... if it:'. The regulation identifies a condition under which an ad MAY be deemed lacking in fair balance; it does not, on its face, impose an absolute placement mandate. The rule statement converts this to 'it must appear on...' and the check to 'as required', which is the classic 'may be misleading' -> 'is prohibited' inflation. Contrast (e)(7) with (e)(6), which the same section frames as conduct that renders an ad false or misleading outright.
- Atomic: a single checkable placement condition, with the two source-permitted placements ('facing another page' OR 'another full page') stated as alternatives rather than as separate requirements. Correct.
- Determinism: whether the distinct risk section occupies a full page or a page facing another page of the same ad is settled by inspecting the layout, not by an impression or adequacy judgment (unlike neighboring (e)(7)(viii) prominence or (e)(7)(ix) adequate emphasis, which would be judgment). 'Deterministic' is defensible, though the reviewer must first identify that the risk information is presented as a 'distinct part'.
- Authority: 21 CFR 202.1 is a regulation, so 'binding' is correct.
- applies_when: 'print' is a fair limit — the provision turns on pages, facing pages and multi-page pagination, which has no analogue in broadcast. Note the rule's own two triggering conditions (ad runs on more than one page; risk information is in a distinct part) live only in the prose, not in applies_when; they are stated in the rule text so this is a structural nit rather than an invented or missing scope limit.
- Severity 'warning' is defensible and is in fact the flag most consistent with the 'may be' framing of (e)(7).
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is operative regulatory text at 21 CFR 202.1(e)(7)(xi), an enumerated condition under the chapeau 'An advertisement may be false, lacking in fair balance, or otherwise misleading ... if it:'. It is not an example, definition, or a statement of what is not required.
- Not overstated: the (e)(7) chapeau is permissive, and the rule statement ('MAY be found lacking in fair balance') and check ('flag as a potential fair-balance deficiency') preserve that hedge instead of stating a flat prohibition. Severity 'warning' matches the permissive framing.
- Atomic: a single disjunctive placement test (facing page OR another full page), gated by the source's own two conditions (ad on more than one page; risk info in a distinct part). The rule correctly does not bundle in the adjacent and distinct obligations of (e)(7)(ix) (emphasis that two facing pages are one ad) or (e)(7)(xii) (info or prominent reference on each page/spread).
- Determinism 'deterministic' is defensible: once gated, whether the risk section faces another page or occupies a full page is a layout fact resolvable by inspection, unlike (e)(7)(vii)-(x) which turn on emphasis, prominence, and adequacy.
- Authority 'binding' is correct: 21 CFR is a codified regulation.
- Locator is correct; the source also contains an unrelated (e)(6)(xi) (literature suggesting unapproved conditions of use), and the rule cites the (e)(7) series properly.
- Defect in applies_when: the source authority is titled 'Prescription-drug advertisements' and 202.1(l)(1) limits coverage to advertisements subject to section 502(n), but neither applies_when, the rule statement, nor the check limits the rule to prescription drug advertising. As written it would be applied to OTC print promotion, which this regulation does not govern.
- The 'print' medium limit and the 'more than one page' condition are justified by the text 'of an advertisement on more than one page' and by 202.1(l)(1)'s enumeration of published journals, magazines, periodicals, and newspapers.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is verbatim item (xi) of the operative list at 21 CFR 202.1(e)(7), whose chapeau reads 'An advertisement may be false, lacking in fair balance, or otherwise misleading or otherwise violative of section 502(n) of the act if it:'. The quote is an operative enumerated failure mode, not an example, definition, or preamble gloss.
- Not overstated: the rule statement and check both preserve the regulation's conditional framing ('MAY be found lacking in fair balance... ', 'flag as a potential fair-balance deficiency') rather than converting (e)(7) into a flat prohibition. The two statutory preconditions — advertisement 'on more than one page' and risk information 'in a distinct part' — are both carried into the rule and the check, and the disjunctive alternative ('or on another full page') is preserved rather than dropped.
- Atomic: one obligation with a disjunctive satisfaction condition (facing page OR another full page). It does not bundle the neighboring, independently checkable duties at (e)(7)(ix) (adequate emphasis that two facing pages are one ad) or (e)(7)(xii) (per-page risk info or prominent reference), which is correct — those warrant separate rules.
- Authority correctly 'binding': 21 CFR 202.1 is a codified regulation, and the source authority is marked binding.
- Locator correct: the quoted sentence is item (xi) under paragraph (e)(7), matching '21 CFR 202.1(e)(7)(xi)'.
- applies_when is justified and appropriately limited: 202.1 governs prescription-drug advertisements, so the prescription-drug class and promotional flags follow from the source; restricting to print is a defensible narrowing given the provision's page/facing-page mechanics, and it is a narrowing rather than an invention.
- Severity 'warning' is defensible: (e)(7) is framed as conduct that 'may be' violative, contrasted with the stricter (e)(6) list, so a flag-for-review posture rather than a hard failure fits the source.
- Determinism is mis-flagged as 'deterministic'. Neither predicate is settled by presence/absence or a literal match: whether risk information constitutes 'a distinct part of the advertisement' (as opposed to being integrated through the body copy) is a structural/interpretive assessment of the layout, and whether a block occupies 'another full page' or sits on 'a page facing another page' of the same advertisement requires reading the mechanical/spread layout (gutters, foldouts, partial pages). The rule's own 'escalate when' clause concedes exactly these judgment calls, which is internally inconsistent with a deterministic flag.